Skip to content

Etravirine

Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor — ANTIINFECTIVES FOR SYSTEMIC USE

Also known as: etravirin, intelence, R-165335, TMC-125

OfpEMA approvedFDA approvedATC J05AG04

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Etravirine is an ofp drug in the Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2008. Its mechanism of action is classified as Cytochrome P450 2C19 Inhibitors, Cytochrome P450 2C9 Inhibitors and Cytochrome P450 3A Inducers. DrugCentral lists 10 molecular targets, including pol, gag-pol and reverse transcriptase. Recorded indications include Human immunodeficiency virus infection.

  • Approval status: ofp (first approved 2008 by the FDA).
  • Drug class: Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor.
  • Mechanism of action: Cytochrome P450 2C19 Inhibitors; Cytochrome P450 2C9 Inhibitors; Cytochrome P450 3A Inducers.
  • Molecular targets: pol, gag-pol, reverse transcriptase and reverse transcriptas (10 listed in DrugCentral).
  • Indications: Human immunodeficiency virus infection.
  • ATC code: J05AG04 (Non-nucleoside reverse transcriptase inhibitors).
  • Molecular formula: C20H15BrN6O; molecular weight 435.29 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

  • Human immunodeficiency virus infection

Contraindications (5)

  • Breastfeeding (mother)
  • Chronic hepatitis C
  • Chronic type B viral hepatitis
  • Liver function tests abnormal
  • Peripheral nerve disease

Mechanism & targets

Mechanism of action (MoA)Cytochrome P450 2C19 Inhibitors; Cytochrome P450 2C9 Inhibitors; Cytochrome P450 3A Inducers; Non-Nucleoside Reverse Transcriptase Inhibitors; P-Glycoprotein Inhibitors
Established pharmacologic classHuman Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor

Molecular targets (10)

TargetGeneActionActivity
Reverse transcriptase/RNaseHpolinhibitorIC50 9.22
Gag-Pol polyproteingag-polunknownIC50 9.00
Reverse transcriptase proteinreverse transcriptaseunknownIC50 8.89
Reverse transcriptasereverse transcriptasunknownIC50 8.00
Cruzipain—unknownIC50 5.40
Canalicular multispecific organic anion transporter 2ABCC3unknownIC50 5.29
ATP-binding cassette sub-family G member 2ABCG2unknownIC50 5.22
Multidrug resistance protein 1ABCB1unknownIC50 5.12
Canalicular multispecific organic anion transporter 1ABCC2unknownIC50 5.11
Multidrug resistance-associated protein 1ABCC1unknownIC50 5.07

Regulatory approvals (2)

DateAgencyMarketed asApplicantOrphan
2008-08-28EMA——
2008-01-18FDA—JANSSEN R AND D

ATC classification

ATC codeTherapeutic hierarchy
J05AG04ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Non-nucleoside reverse transcriptase inhibitors

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Virologic failure987.7
Lipodystrophy acquired736.5
Viral mutation identified637.7
Progressive external ophthalmoplegia488.3
Mitochondrial toxicity486.2
Drug resistance467.1
Pathogen resistance428.3
Eyelid ptosis335.8
CD4/CD8 ratio decreased295.6
CD4 lymphocytes decreased257.7
Drug interaction253.0
Enlarged clitoris207.3

Chemical structure

Molecular formulaC20H15BrN6O
Molecular weight435.29 g/mol
CAS number269055-15-4
InChIKeyPYGWGZALEOIKDF-UHFFFAOYSA-N
PubChem CID193962
CC1=CC(=CC(C)=C1OC1=NC(NC2=CC=C(C=C2)C#N)=NC(N)=C1Br)C#N

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Etravirine used for?

DrugCentral lists the following indications for Etravirine: Human immunodeficiency virus infection.

How does Etravirine work?

Etravirine is classified as Cytochrome P450 2C19 Inhibitors, Cytochrome P450 2C9 Inhibitors and Cytochrome P450 3A Inducers; its molecular targets in DrugCentral include pol (inhibitor), gag-pol, reverse transcriptase and reverse transcriptas.

When was Etravirine first approved?

Etravirine was first approved by the FDA in 2008.

What drug class does Etravirine belong to?

Etravirine is in the Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class.

What is the chemical formula of Etravirine?

Etravirine has the molecular formula C20H15BrN6O and a molecular weight of 435.29 g/mol.

Browse: all drugs starting with E · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFP
First approval2008-01-18
AgencyFDA
Targets10
Indications1
FormulaC20H15BrN6O
DrugCentral ID1115
Interactive profile